Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) and Harmony Biosciences (NASDAQ:HRMY – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.
Risk and Volatility
Astellas Pharma has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.
Earnings and Valuation
This table compares Astellas Pharma and Harmony Biosciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Astellas Pharma | $14.21 billion | 2.16 | $1.83 billion | $1.36 | 12.46 |
| Harmony Biosciences | $868.45 million | 2.23 | $158.69 million | $3.02 | 10.91 |
Astellas Pharma has higher revenue and earnings than Harmony Biosciences. Harmony Biosciences is trading at a lower price-to-earnings ratio than Astellas Pharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Astellas Pharma and Harmony Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Astellas Pharma | 16.18% | 26.13% | 13.32% |
| Harmony Biosciences | 18.05% | 18.55% | 13.24% |
Analyst Ratings
This is a breakdown of current ratings for Astellas Pharma and Harmony Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Astellas Pharma | 0 | 3 | 0 | 1 | 2.50 |
| Harmony Biosciences | 1 | 6 | 6 | 0 | 2.38 |
Harmony Biosciences has a consensus target price of $48.00, indicating a potential upside of 45.63%. Given Harmony Biosciences’ higher probable upside, analysts plainly believe Harmony Biosciences is more favorable than Astellas Pharma.
Insider & Institutional Ownership
86.2% of Harmony Biosciences shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Harmony Biosciences beats Astellas Pharma on 8 of the 15 factors compared between the two stocks.
About Astellas Pharma
Astellas Pharma Inc. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company was formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, and is headquartered in Tokyo. Astellas develops treatments across areas including oncology, urology, immunology and women’s health. Its medicines include Xtandi (enzalutamide), used to treat certain forms of prostate cancer, and Prograf (tacrolimus), an immunosuppressant used in organ transplantation.
About Harmony Biosciences
Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for people living with rare neurological diseases. The company’s work centers on therapies intended to address significant unmet medical needs. Its lead product, WAKIX (pitolisant), is approved in the United States to treat excessive daytime sleepiness or cataplexy in adults and pediatric patients aged 6 years and older with narcolepsy. Harmony launched WAKIX in the United States in 2019. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony primarily serves the U.S. market.
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
